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 ABSTRACT
About 30 years ago, the treatment of chronic renal disease anaemia was revolutionized by the introduc-
tion of recombinant human erythropoietin, which reduced the need for blood transfusions. In spite of this 
huge advance, the first recombinant human erythropoietin has a relatively short half-life and needs to be 
administered two to three times per week. Subsequently, other molecules were developed, such as darbe-
poetin alfa, continuous erythropoietin receptor activator (CERA) and peginesatide, with longer half-life, but 
the route of administration still remains a problem. Erythropoietin has an action that exceeds erythropoiesis 
and plays an important role in cell protection. Based on knowledge of the molecular mechanisms that 
control erythropoiesis, namely the regulation of EPO gene expression, through HIF system, GATA-2 and 
NF-kB, several upcoming therapeutic agents and strategies for stimulating and treating anaemia emerged. 
The main effort in developing these treatments is to achieve other routes of administration, more conveni-
ent for the patient, such as oral therapy, not disregarding an easier production, storage and frequency of 
administration. Some of them are still in laboratory phase and others already in clinical trials phase II or 
III. In this work, based on a literature search of studies using MEDLINE, our objective is to review the regu-
lation of erythropoietin production and its functions, as well as treatment approach for anaemia of chronic 
kidney disease, with particular focus on new therapies.
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 RESUMO
Há cerca de 30 anos atrás, o tratamento da anemia da doença renal crónica foi revolucionado pela 
introdução da eritropoietina (EPO) humana recombinante que permitiu reduzir drasticamente a necessidade 
de transfusões sanguíneas. Apesar deste grande avanço, a primeira EPO humana recombinante tem uma 
semivida relativamente curta e tem de ser administrada duas a três vezes por semana. Subsequentemente, 
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 INTRODUCTION
Erythropoietin (EPO), formerly named haemopoi-
etin is essential to erythropoiesis. Since its discovery, 
much has been achieved in the knowledge of the 
biology of this glycoprotein. Currently, we know that 
EPO has an action that exceeds erythropoiesis and 
plays an important role in cell protection.
New erythropoietic agents designed to modulate 
the activation of the EPO gene are being studied. 
Knowing that EPO has other functions, and also that 
regulators of the EPO gene are at the same time 
regulators of many other genes, we present a review 
on this issue. We will mainly focus on EPO produc-
tion, regulation and functions, taking also into 
account current therapies and new options for anae-
mia treatment.
 Erythropoietin
Erythropoietin is a hormone that controls erythro-
cytes production, promoting survival, differentiation 
and proliferation of erythroid progenitor cells in the 
bone marrow. Apoptosis prevention of these cells is 
the main mechanism underlying its function1. The 
human EPO gene, located on chromosome 7 codes for 
EPO, a protein composed of 165 amino acids, heavily 
glycosylated, with a molecular mass of about 30 kDa2.
In adults, EPO is primarily synthesized in the kid-
ney. Previous studies showed conflicting results 
about renal EPO-producing cells (REPC), but the 
predominant location reported was the peritubular 
interstitial fibroblasts3 and tubular epithelial cells, 
mainly present in renal cortex (predominantly in the 
juxtamedullary region) and in outer medulla. Beirão 
et al. observed that distal nephron (epithelial distal 
tubular cells and collecting tubules) was the main 
locus of erythropoietin production in normoxic human 
kidneys4. In 2014, Nagai et al. reevaluated erythro-
poietin production and confirmed that erythropoietin 
is produced by cortical nephrons in normal haema-
topoietic condition, mainly by intercalated cells and 
not in peritubular cells as previously suggested. The 
production by peritubular cells occurred under hypox-
ic conditions, suggesting a different regulation mech-
anism between the nephrons and peritubular cells5. 
During fetal life, EPO is produced by the liver. Simi-
larly to the kidney, the liver responds to hypoxia 
increasing the number of EPO hepatocyte producers, 
located around the central vein. Erythropoietin was 
also found in liver stellate cells, previously called 
Ito cells6. In adult livers, EPO mRNA levels increase 
under moderate to severe hypoxia conditions, being 
one of the most important sources of extrarenal EPO, 
although insufficient to normalize haemoglobin in 
chronic kidney disease (CKD).
Apart from the kidney, EPO mRNA expression was 
also detected in non-haematopoietic tissues, such as 
brain (neurons and glial cells), lungs, heart, bone mar-
row, spleen, hair follicles, reproductive system, pan-
creatic islets and osteoblasts7,8. Under basal condi-
tions, these cells do not play any role in erythropoiesis, 
foram desenvolvidas outras moléculas, como a darbepoetina alfa, o ativador contínuo do EPO-R (CERA) e 
o peginesatide, com uma semivida mais longa, mas a via de administração continua a ser exclusivamente 
parenteral. A eritropoietina desempenha várias funções além da eritropoiética. Tendo por base os mecanis-
mos moleculares que controlam a eritropoiese, nomeadamente a regulação da expressão do gene da EPO, 
através do sistema do HIF, GATA-2 e NF-kB, surgiram vários fármacos e estratégias terapêuticas para o 
tratamento da anemia. O principal objetivo destes novos tratamentos passa por desenvolver outras vias 
de administração, mais cómodas para o doente, como a terapia oral, e facilitar a produção, armazenamento 
e frequência de administração dos fármacos. Alguns destes ainda se encontram em fase laboratorial, 
enquanto outros já estão em ensaios clínicos fase II ou III. Neste trabalho, baseado na revisão bibliográfica 
de artigos científicos publicados na MEDLINE, procuramos rever a regulação da produção da EPO e respe-
tivas funções, bem como abordar o tratamento da anemia da doença renal crónica, com especial enfoque 
nas novas terapêuticas.
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but may contribute to induce stress erythropoiesis9. 
In fact, EPO synthesized by these cells tends to act 
more locally, modulating, for example, regional angio-
genesis and cell viability10.
  Erythropoietin: Hematopoietic and cytoprotective 
functions
Erythropoietin is an endocrine, paracrine and auto-
crine hormone that acts as a cytoprotective hormone 
overextending its haematopoietic function. Among 
other effects, EPO antagonizes the activity of pro-
inflammatory cytokines, has neuroprotective func-
tions and promotes healing through stimulation of 
angiogenesis and capillary growth, has direct effects 
on immune, endothelial and bone marrow stromal 
cells, as well as on heart, brain, reproductive system, 
gastrointestinal tract, muscle, kidney, pancreas and 
nervous system cells7. Erythropoietin acts co-ordi-
nately at various levels, which includes: limiting 
molecule production, such as reactive oxygen species 
and glutamate11, reversing vasospasm, attenuating 
apoptosis, modulating inflammation and recruiting 
stem cells12. It has other non-erythropoietic biological 
functions, like mitogenesis and angiogenesis, in part 
via endothelin-1 induction. Thus, anticipating an 
ischaemic insult (for example, kidney transplantation 
or renal arteries clamping during abdominal surgery), 
recombinant EPO can be used as a kidney tissue 
protector. Similarly, it may play an important role 
reducing CKD oxidative stress and vascular dysfunc-
tion. Erythropoietin prevents tubular epithelial cells 
apoptosis and stimulates surviving cell population 
mitotic activity13. In the central nervous system, EPO 
is involved in neuroprotection, neurogenesis and 
angiogenesis, playing an important function as a 
neurotropic and immunomodulatory factor12. Angio-
genesis promotes neurovascularization, allowing 
ischaemic zone revascularization and increased oxy-
gen supply. At the same time, there is an increase 
in neural stem cells production and astrocytes and/
or oligodendrocytes differentiation14. Erythropoietin’s 
protective effects were studied in vitro using adult 
rat cardiomyocytes and in vivo employing a rat model 
of coronary ischaemia–reperfusion. Erythropoietin’s 
anti-apoptotic activity reduces cardiomyocyte loss 
by about 50%, resulting in normalization of haemo-
dynamic function. Due to cell death reduction, both 
compensatory hypertrophic response and inflamma-
tion are attenuated, preventing a misfit remodelling15. 
In the skin, EPO enhances wound healing, reduces 
inflammatory response and increases capillary density 
in ischaemic regions. It promotes cardiac and central 
nervous system development, improves learning and 
memory, regulates angiogenesis, protects from 
ischaemia/reperfusion injury and retina from degen-
eration16. It also protects against diabetes in mouse 
models, mediated by Janus Kinase-2 (JAK2) signalling 
directly in pancreatic cells, resulting in cell survival 
and proliferation, reduced inflammation and increased 
angiogenesis in the islets17. Erythropoietin may act 
on the regulation of metabolism and obesity and 
has potential benefits in the treatment of neurologic 
diseases, mood symptoms and depression (Fig. 1). 
Therefore, EPO has an action that exceeds erythro-
poiesis and plays an important position in cell pro-
tection, using for that different cell receptors in 
erythropoiesis and cellular protection. This knowl-
edge allowed the development of modified recom-
binant human EPO that only acts in cell protection, 
such as asialo-EPO, carbamylated EPO (CEPO) and 
neuro-EPO, a subject that goes beyond the scope 
of this work.
 EPO gene regulation
Erythropoietin production is primarily stimulated 
by hypoxia and controlled transcriptionally. According 
to hypoxia severity, serum levels can increase up to 
several hundred times.
Figure 1
Erytropoietin targets and receptors used for each action. Erythroid cells are 
stimulated via classical EPO receptor (EPO-R) while EPO acts on the other 
cells by CD131 EPO-R activation (adapted from Broxmeyer HE. Erythropoie-
tin: multiple targets, actions, and modifying influences for biological and 
clinical consideration. J Exp Med 2013; 210(2):205-208).
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Hypoxia inducible factor (HIF) system: Once EPO 
binds to the EPO receptor (EPO-R) dimer, it induces 
JAK2 tyrosine kinase stimulation, leading to various 
proteins phosphorylation, including EPO-R itself. 
Thus, different intracellular pathways are activated: 
signal transduction and activator of transcription 5 
(STAT 5), phosphatidylinositol-3-kinase/Protein 
kinase B (PI-3K/Akt), Mitogen-Associated Protein 
Kinase/extracellular signal-related kinase (MAPK/ERK) 
and protein kinase C18. JAK2 activation also originates 
multiple binding sites for intracellular signalling pro-
teins with src homology 2 (SH2) domains1. Erythro-
poietin enhancer (3’) is activated by HIF, a heterodi-
meric protein that contains the basic helix-loop-helix 
domain and belongs to the transcription factors PAS 
[PER/aryl hydrocarbon receptor nuclear translocator 
(ARNT)/single minded (SIM)] family. It is composed 
of an O2-regulated HIF-1α subunit and a constitutively 
expressed HIF-1β subunit. Three α subunits are 
known: HIF-1α, HIF-2α and HIF-3α. Together with 
HIF-2α, HIF-1α facilitates oxygen delivery and cellular 
adaptation to hypoxia, stimulating a broad spectrum 
of biological processes. In fact, the number of known 
genes activated by HIF continues to increase and 
includes genes whose proteins are involved in angio-
genesis, energy metabolism, erythropoiesis, cell pro-
liferation and viability, mitochondrial biogenesis, 
vascular remodelling and vasomotor responses19. 
Erythropoiesis and angiogenesis represent adaptive 
responses to improve tissue oxygenation, which 
require several days to develop – for example, the 
time required to the appearance of mature red blood 
cells in the circulation, mediated by EPO, is about 
a week. The HIF also mediates adaptive responses 
to hypoxia in a short term, regulating transcription-
ally a large number of glucose transporters (GLUT-1,3) 
and glycolytic enzymes, as well as cell growth and 
survival genes (insulin-like growth factor 2 (IGF-2), 
insulin-like growth factor-binding protein (IGFBP) and 
transforming growth factor-α (TGF-α))20. Glycolytic 
enzymes induction demonstrates the role of HIF in 
the autonomous cellular adaptation to hypoxia, pro-
ducing ATP by glycolysis, instead of oxidative phos-
phorylation. The HIF activated genes are also involved 
in crucial aspects of cancer biology, such as angio-
genesis, cell survival, glucose metabolism and inva-
sion21 and HIF regulated genes are induced when 
HIF heterodimers bind to specific DNA sequences 
and transcriptional cofactors are recruited. These 
sequences are found in regulatory regions of various 
genes, oxygen sensitive, and are called the hypoxia 
response elements (HRE)2. In normoxic conditions, 
HIF subunits are rapidly degraded by proteasomes, 
after binding with von Hippel-Lindau tumour sup-
pressor (VHL), which is the recognition substrate of 
the ubiquitin E3 ligase complex that mediates the 
ubiquitination of HIF. This ubiquitination prevents 
transcriptionally active heterodimer formation and 
requires hydroxylation of specific proline residues 
(Pro 402 and Pro 564 in HIF-1α; Pro 405 and Pro 
531 in HIF-2α), which are located in oxygen-depend-
ent degradation domains (ODD: lying on HIFα ter-
minal C)22. The HIF inactivation by hydroxylation is 
carried out by three main 2-oxoglutarate (2OG) 
dependent oxygenases – prolyl-4-hydroxylase domain 
proteins (PHD) – PHD1, PhD2 and PHD3, which work 
as primary oxygen sensors, in the control of EPO 
production. The PHD are expressed in the kidney, 
where they control HIF activity23. In hypoxic condi-
tions, hydroxylation is inhibited and HIF signalling 
is activated. A second HIF transcription pathway is 
related with factor inhibiting HIF (FIH). It is a 2OG 
oxygenase which catalyzes the hydroxylation of an 
asparginine residue, belonging to the transactivation 
domain of HIFα carboxyl terminal, that inhibits coac-
tivators CREB-binding protein (CBP)/p300 binding to 
its transcriptional complex. Therefore, the opposite 
– HIF inactivation – facilitates CBP/p300 selection, 
resulting in increased HIF target gene expression, 
under hypoxia. In the kidney, FIH was detected in 
REPC, podocytes and distal tubule24. Although in 
vitro studies have identified HIF-1 as the responsible 
transcription factor for EPO induction in hypoxia 
conditions, HIF-2 has now emerged as the main 
regulator of EPO production, in vivo25. In fact, it is 
responsible for the prevention of erythroid progenitor 
cells apoptosis and the maintenance of a normal 
erythropoiesis, increasing erythrocytes production, 
under hypoxia10. Its transactivation in EPO HRE 
involves multiple nuclear factors that are associated 
with EPO gene. One of these factors is hepatocyte 
nuclear factor-4 (HNF4) that binds to the EPO enhanc-
er, allowing interaction with HIF-2. As HIF-2, the 
cellular location of HNF4 expression corresponds with 
EPO production places in the kidney and liver. Low 
intracellular iron levels decrease HIF-2α translation, 
limiting both EPO production and erythropoiesis, 
when cellular iron stores are depleted, because, 
physiologically, erythropoiesis does not occur in the 
absence of iron. Besides HIF, EPO expression is also 
regulated by GATA-2 and nuclear factor kappa beta 
(NF-kB) at the level of the promoter. The EPO 
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promoter (5’) is suppressed by GATA-2 in normoxia 
conditions and, under hypoxia, GATA-2 levels 
decrease. The pro-inflammatory cytokines interleu-
cine-1 (IL-1) and tumour necrosis factor-α (TNF-α) 
activate GATA-2 and NF-kB and may contribute to 
the anaemia of chronic disease in part by suppress-
ing EPO production26.
Hepcidin: The EPO production in the kidney and 
liver stimulates erythropoiesis and an additional need 
for iron that leads to an increase in intestinal iron 
absorption and iron binding capacity, as well as an 
increase in iron release from body iron stores. The 
EPO production is coordinated with iron metabolism 
by hepcidin, the systemic iron homeostasis regulator, 
encoded by the HAMP gene. It is a small peptide 
consisting of 25 amino acids, mainly produced by 
hepatocytes, whose transcription is sensitive to iron 
and oxygen. In addition to its antimicrobial proper-
ties, hepcidin controls the amount of iron absorbed 
in the duodenum and the release of iron from the 
reticuloendothelial system cells (such as Kupffer cells 
and splenic macrophages) by ferroportin internaliza-
tion and degradation, which is expressed in duodenal 
enterocytes, hepatocytes and macrophages27. The 
hepcidin regulation is complex, but one of the major 
stimulus for its production is IL-6 (via JAK/STAT tran-
scription), produced as part of the inflammatory 
response, together with molecules like hemojuvelin 
and bone morphogenetic protein 6 (BMP-6). The 
hemojuvelin binds competitively to the BMP, which 
prevents the signalling of its receptor and suppresses 
hepcidin production28. In case of iron deficiency (such 
as iron deficiency anaemia) and/or hypoxic condi-
tions, the liver decreases hepcidin production and 
intestinal iron absorption is enhanced. Increased 
serum hepcidin levels were observed in chronic situ-
ations frequently associated with inflammatory condi-
tions, which reduces ferroportin expression and 
causes hypoferremia, supporting the key role of 
hepcidin in the pathogenesis of chronic disease 
anaemia29.
 ANAEMIA OF CKD
Anaemia is defined as a haemoglobin concentra-
tion below 12 g/dl in women and less than 13 g/dl 
in men30. A large proportion of CKD patients develop 
anaemia over the course of their disease, which is 
a risk factor associated with worse prognosis, either 
as an independent predictor factor or as a risk mul-
tiplier in patients with concomitant cardiovascular 
disease31. Anaemia prevalence increases as renal 
function worsens to glomerular filtration rate lower 
than 60ml/min/1.73 m2 and is almost universal in 
stage 5 CKD32. Anaemia severity is related to glo-
merular filtration loss degree, but independent of 
kidney disease aetiology.
The CKD anaemia is hypoproliferative and normo-
cytic normochromic, unless an iron deficiency is 
overlapped. Although multifactorial (haematinic defi-
ciencies, shortened erythrocyte survival, low grade 
haemolysis, bleeding), the leading cause for CKD 
anaemia is the insufficient EPO production, due to 
decreased EPO gene expression33. The EPO gene 
activation in renal cells depends of microenviron-
mental signals and is not constitutively expressed, 
a possible reason why an adequate renal EPO-pro-
ducing cell line is not available. In CKD, the cellular 
phenotype of REPCs changes to a pathologic fibro-
genic state, leading to collagen production and fibro-
sis, which results in loss of EPO synthesis capacity. 
Additionally, the uraemic environment associated 
with chronic inflammatory status contributes for 
erythrocyte survival decrease and erythropoiesis inhi-
bition. In fact, in CKD patients, IL-1, IL-6 and TNF-α 
levels are significantly amplified by the decrease in 
its clearance and the increase in its production34. 
These pro-inflammatory cytokines contribute to anae-
mia and EPO resistance. Furthermore, renal failure 
itself contributes to inflammation with an increase 
in advanced glycation end products (AGE), a reduc-
tion in plasma antioxidant activity and loss of anti-
oxidants such as zinc, selenium and vitamins C and 
E. This inflammatory status leads to an increase in 
hepcidin release by the liver, with consequent serum 
ferritin increase and restriction on iron availability 
for erythropoiesis35. The fibrosis of bone marrow 
induced by secondary hyperparathyroidism can exac-
erbate the anaemia33.
 TREATMENT
Recombinant human EPO (rHu-EPO) was intro-
duced as a treatment for CKD in 1989 (US) and 1990 
(in Europe). Until then, anaemic patients were pri-
marily controlled with blood transfusions and, to a 
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lesser extent, with anabolic steroids, both methods 
with severe limitations. Regular transfusions increased 
the risk of infection, iron overload and anti-HLA 
(human leukocyte antigen) antibodies development, 
reducing the likelihood of a successful renal trans-
plantation. Steroid therapy, of limited efficacy, pre-
sented important side effects, such as hirsutism, 
virilization and hepatotoxicity, and was withdrawn36. 
Currently, the pharmacological treatment for anaemia 
in CKD includes therapy with erythropoiesis stimulat-
ing agents (ESA) and supplementation with iron.
Erythropoiesis stimulating agents (ESA): all the 
agents able to increase, directly or indirectly, the 
EPO-R action. They are glycoproteins, manufactured 
by recombinant DNA technology, with the same bio-
logical activity as endogenous EPO.
To minimize possible risks of EPO therapy, the 
lowest effective dose possible should be used, seek-
ing an increase in haemoglobin concentration near 
1 g/dl per month. Full correction of anaemia with Hb 
> 13 g/dl may be associated with increased risk of 
cardiovascular and thromboembolic events30,37. The 
initial dose of EPO depends on the type of ESA and 
its administration should be considered when hae-
moglobin level is < 10 g/dl30. In haemodialysis 
patients the intravenous route is preferred, but the 
subcutaneous administration can substantially reduce 
dose requirements and is the preferred administra-
tion route in pre-dialysis, transplant or peritoneal 
dialysis patients, for economic and practical reasons. 
In CKD and cancer patients, this treatment is associ-
ated with an increased morbidity: thrombosis and 
cardiovascular events (myocardial infarction, stroke 
and heart failure) and mortality. The risk of death 
or cardiovascular events is associated with a poor 
initial haematopoietic response, with increased ESA 
doses to achieve the target haemoglobin levels38. 
Due to risk of tumour growth, rHu-EPO should be 
carefully evaluated in neoplasia setting. Erythropoi-
etin blocks tumour cells apoptosis and potentiates 
angiogenesis, with increased tumour growth, metas-
tases and reduction of the radiotherapy response39. 
Hypertension and deep vein thrombosis incidence 
may also increase and antithrombotic prophylaxis in 
surgical patients treated with rHu-EPO should be 
considered40.
Besides CKD anaemia, rHu-EPO is currently indi-
cated for anaemia in patients undergoing elective 
surgeries and cancer patients with chemotherapy-
induced anaemia to reduce blood transfusions41. 
The first available drugs were epoetin alfa and 
epoetin beta, two forms of recombinant EPO, both 
highly effective, but with a short duration of action 
(administration 3 times a week: approximate half-
life of 8 hours)37. In 2001, a second-generation ESA 
emerged: darbepoetin alfa. It is a hyperglycosylated 
EPO analogue with a higher number of sialic acid 
residues, which improves its biological potency. 
Regarding the mechanism of action, it acts as the 
native EPO, stimulating its receptor. Due to its high 
metabolic stability, it has a greater half-life time 
compared to conventional EPO and may be admin-
istered once every two weeks42. In 2007, the Food 
and Drug Administration (FDA) approved the third 
generation agent CERA (continuous activator EPO-
R)/PEG-EPO (methoxypolyethylene glycol-epoetin 
beta), which acts also in the EPO-R. It consists of 
epoetin beta “PEGylated” (connected to the polymer 
polyethylene glycol), which increases half-life: about 
130 hours after the administration, by intravenous 
or subcutaneous routes. Thus, it can be adminis-
tered every two weeks or every month, during the 
maintenance phase of treatment43. Another of the 
agents approved by FDA was peginesatide, in 2012. 
This is a synthetic peptide “PEGylated”, with no 
homology to EPO, but equally capable of stimulat-
ing its receptor, initiating a similar intracellular 
signalling cascade (also called as EPO mimetic)44. 
Its advantages include low immunogenicity and easy 
production, without the need for cell cultures and 
genetic engineering techniques and, as CERA, 
peginesatide could be administered monthly. How-
ever, since March 2013, this treatment can only be 
given to patients on dialysis due to hypersensitivity 
reactions associated with injection, 0.02% of them 
fatal45.
 New erythropoietic stimulators
The new erythropoietic stimulators, summarized 
in Table I, search for continuous activation of EPO 
gene, by activating the EPO enhancer (3’) through 
HIF stabilizers or inhibiting GATA-2, responsible for 
inhibiting EPO gene expression acting on its pro-
moter. Apart from modulation of EPO gene, the 
modulation of hepcidin expression, involved in the 
genesis of anaemia and EPO resistance, has been 
actively searched.
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HIF stabilizers: The EPO production is controlled 
by transcriptional and post-transcriptional oxygen-
dependent mechanisms. The EPO gene transcription 
is activated by HIF. In normoxia, HIF α chain is hydroxy-
lated by PHD, degraded by proteasome and inacti-
vated. In hypoxia, α chain is not degraded and binds 
to β chain (constitutively expressed), leading to HIF 
activation and induction of EPO expression. The PHD 
inhibition results in HIF stabilization and EPO gene 
transcription. Agents that prevent HIF degradation are 
called HIF stabilizers. Several HIF stabilizers com-
pounds have been studied. One of the first candidates 
was FG-2216, synthesized by FibroGen46. Administra-
tion of FG-2216 stabilizes HIF, promoting EPO gene 
transcription and increasing its synthesis. Thus, these 
molecules are capable of increasing endogenous EPO 
levels without needing an ESA. These agents have 
the advantage of being orally active, which represents 
a potential non-injectable therapy in the future. Fur-
thermore, they are able to modulate other genes 
involved in erythropoiesis, in particular those related 
with iron utilization: transferrin, transferrin receptor, 
ferroportin and DMT1 (divalent metal transporter-1) 
and increase the iron availability.
However, there are disadvantages to be men-
tioned: in phase 2 clinical trial of FG-2216, one patient 
developed a fatal hepatic necrosis, temporally associ-
ated with HIF stabilizer administration46. In addition, 
several hundreds of hypoxia sensitive genes are also 
activated by PHD inhibition, including those involved 
in glucose regulation, angiogenesis, etc. One of the 
major concerns is related to possible vascular 
endothelial growth factor (VEGF) activation, which 
may enhance tumour growth and proliferative dia-
betic retinopathy. A second generation HIF stabilizer: 
FG-4592, presented as Roxadustat in 2013, is also 
orally administered and is in phase 3 trials. It acts 
simultaneously on erythrocytes production and iron 
incorporation, correcting anaemia and maintaining 
haemoglobin levels without needing IV iron sup-
plementation, in pre-dialysed or dialysed patients. 
The endogenous EPO production stimulation results 
in lower serum levels, when compared with rHu-EPO, 
which may be important to reduce side-effects, 
namely cardiovascular events, stroke or increased 
blood pressure, which requires introduction or inten-
sification of antihypertensive therapy47.
GATA-2 inhibitors: The ability to positively regulate 
the EPO gene, through GATA-2 inhibition, has also 
been investigated. GATA-2 inhibits EPO gene expres-
sion, by acting on its promoter, so its inhibition can 
stimulate EPO gene expression and its production, 
enhancing erythropoiesis. There are two GATA inhibi-
tors reported: K-7174 and K-11706. They have dem-
onstrated to enhance EPO production and its pro-
moter, previously suppressed by IL-1 and TNF-α. Oral 
administration was able to restore haemoglobin 
concentration, reticulocyte count, EPO levels and 
CFU-E (colony-forming unit erythroid) numbers. 
K-11706 appears to cause a greater hypoxic induc-
tion, probably because it also stimulates HIF-1, 
besides GATA inhibition48. However, there is the 
possibility of promoting activation of other genes, 
like VEGF, as described with HIF stabilizers, further 
studies being needed.
Hepcidin modulators: Hepcidin is one of the mol-
ecules involved in anaemia genesis and endogenous 
EPO resistance. Thus, a suppressive therapy of hep-
cidin may be able to increase removal of iron from 
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Table I
New erythropoiesis stimulating agents for treatment of anaemia of CKD
Class Molecule/drug Development phase studies
HIF stabilizers
FG-2216 II
FG-4592 III
GATA inhibitors
K-7174
Pre-clinical
K-11706
Hepcidin modulators
Decreased production
Non-anticoagulant heparine Pre-clinical
Dorsomorphin LDN-193189 Pre-clinical
Tocilizumab Pre-clinical
Neutralization
Monoclonal antibody I
Anticaline PRS-080 I
Spiegelmer NOX-H94 II
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its storage and allow iron uptake from a normal diet. 
It is a potential alternative to IV iron requirement, 
which reduces risk and side effects associated to 
this treatment, restoring effectiveness of oral iron 
therapy and increasing iron release from the reticu-
loendothelial system49.
Several strategies to antagonize hepcidin effect 
have been described. The decrease in production can 
be achieved by interfering in regulatory pathways. 
Heparin, a widely used anticoagulant, is a potent 
inhibitor of hepcidin expression in liver cell lines and 
in mice, due to its binding capacity to BMPs. In five 
patients treated with low-molecular-weight heparin 
for deep venous thrombosis prophylaxis, serum hep-
cidin decreased 80 to 85%, 2 to 5 days after initiating 
treatment, with a concomitant increase in serum iron 
levels and transferrin saturation. Hepcidin inhibition 
and iron increase can be attributed to both anti-
inflammatory activity of heparin, by IL-6 reduction, 
and anti-hepcidin activity through BMP sequestra-
tions50. In spite of the safety profile of heparin, its 
anticoagulant activity impairs a wider application and, 
for that, it was developed a non-anticoagulant heparin 
molecule, by “glycol-split”, maintaining BMPs modula-
tion ability, which resulted in hepcidin suppression 
in vitro and in vivo, in mice, even in inflammatory 
environment, with minimal or no toxicity. Non-anti-
coagulant heparins have anti-hepcidin, anti-inflam-
matory and anti-tumour properties, representing a 
therapy for inflammatory anaemia in chronic diseases 
and cancer51.
Hepcidin regulation is modulated by BMP-6 and 
IL-6. This knowledge led to development of therapies 
directed to these targets. One example is dorsomor-
phin, a small molecule that inhibits BMP type I recep-
tor and reduces hepcidin expression in inflammatory 
models and generalized inflammatory response itself. 
A dorsomorphin derivative, DLD-193189, has shown 
to inhibit excessive BMP signaling52 and, when used 
in anaemic rats for 4 weeks, produced increases in 
serum iron concentration and ferroportin expression, 
as well as an improvement in haemoglobin and 
haematocrit. However, besides blocking BMP path-
way, it also potently inhibits VEGF and MAPK/ERK 
components53. Thus, contrary to what was thought, 
it is not a BMP specific inhibitor, representing the 
major challenge of these agents. Interruption of hep-
cidin gene activation, by IL-6, has also been pro-
posed54. Tocilizumab, an IL-6 neutralizing antibody, 
approved for rheumatoid arthritis treatment, decreas-
es hepcidin levels in a rapid and prolonged way, 
with anaemia improvement in Castleman’s disease. 
It is a rare lymphoproliferative disorder characterized 
by IL-6 excessive production and elevated hepcidin 
serum levels, associated with microcytic hypochromic 
anaemia. The major complication of blocking IL-6 
activity seems to be an increased risk of infections55, 
so this therapy should be confined to the treatment 
of serious diseases.
Hepcidin neutralization by an antihepcidin mono-
clonal antibody, tested in a mouse model of inflam-
matory anaemia (caused by Brucella abortus heat-
killed), overcame EPO resistance. In monotherapy, it 
has a limited activity, but, when administered with 
an ESA, it demonstrated efficacy in anaemia treat-
ment56. Lipocalins are small extracellular proteins 
that exhibit a binding site with high structural plastic-
ity. Due to its simple structure and ability to recognize 
and bind to various organic compounds, they are a 
good class of therapeutic proteins for specific blocks. 
PRS-080 anticalin is a lipocalin derivative that binds 
specifically to human hepcidin. In monkeys, its admin-
istration resulted in effective iron mobilization, with 
increased serum levels57. It is a recent therapeutic 
approach, needing studies for safety, tolerability and 
efficacy assessment. The first human clinical trial 
began in 2013. Another strategy consists of synthetic 
oligonucleotides PEGylated – spiegelmers – that bind 
specifically, and with high affinity, to hepcidin. This 
binding blocks hepcidin-induced ferroportin degrada-
tion, leading to increased serum iron concentration58. 
These therapeutic agents are attractive due to high 
resistance to nucleases, good stability in vivo and 
low immunogenicity. The anti-hepcidin spiegelmer 
NOX-H94 was tested in monkeys with anaemia, caused 
by IL-6 daily injection, for 7 consecutive days. Con-
comitant administration of NOX-H94 decreased anae-
mia development59. In a phase I trial, NOX-H94 
administration was safe and well tolerated, and after 
a single dose, there was a dose-dependent increase 
in serum iron and transferrin saturation. However, 
spiegelmers administration leads to oligonucleotides 
accumulation in macrophages, throughout the body, 
being unknown whether this chronic systemic admin-
istration results in adverse effects60. Finally, these 
experimental treatments for anaemia in CKD are not 
free of risks. Greater iron availability can promote or 
worsen infections, so each intervention should be 
properly assessed.
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 CONCLUSIONS
The introduction of rHu-EPO revolutionized the 
treatment of CKD patients, enabling a long-term safe 
management of anaemia, without risks associated 
with blood transfusions. Since then, several ESAs 
have appeared, characterized by lower administration 
frequency and better stabilization of haemoglobin 
concentration. New therapeutic strategies include HIF 
stabilizers and other non-injectable approaches, and 
it is expected, in a short term, the availability of an 
oral therapy, providing greater comfort to patient 
and treatment compliance.
Since iron availability is a limiting factor and its 
supplementation is usually necessary to ensure an 
adequate response to EPO, combination of different 
classes of agents can be an approach to equate. For 
example, the combination of an HIF stabilizer with 
a hepcidin modulator can potentiate the therapeutic 
effects, overcoming iron restriction.
The potential of erythropoiesis stimulation remains 
under investigation and it is expected that develop-
ment and improvement of new therapies result in 
improved quality of life of patients. Further studies 
are needed to assess safety and long-term results, 
in order to apply these treatments to patients with 
anaemia of CKD.
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